Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner AS's Other Operating Expense for the
six
months ended in Dec. 2025 was €-1.59 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0.41 Mil.
J.Molner AS's quarterly Other Operating Expense
increased
from Dec. 2024 (€1.57 Mil) to Jun. 2025 (€2.00 Mil) but then
declined
from Jun. 2025 (€2.00 Mil) to Dec. 2025 (€-1.59 Mil).
J.Molner AS's annual Other Operating Expense
increased
from Dec. 2023 (€1.91 Mil) to Dec. 2024 (€2.92 Mil) but then
declined
from Dec. 2024 (€2.92 Mil) to Dec. 2025 (€0.41 Mil).
J.Molner AS Other Operating Expense Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €0.41 Mil mean?
J.Molner AS (OTSE:MOLNR) has a Other Operating Expense of €0.41 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on J.Molner AS and its competitors.
Is J.Molner AS's Other Operating Expense too high?
J.Molner AS's current Other Operating Expense is €0.41 Mil. Overall, J.Molner AS has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Other Operating Expense compare to ZTS and UTHR?
J.Molner AS's Other Operating Expense of €0.41 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on J.Molner AS and its competitors. J.Molner AS's current Other Operating Expense is €0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.67, compared to a current price of €18.00 — trading 8.5% below its estimated fair value. The current Other Operating Expense is €0.41 Mil. J.Molner AS's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Other Operating Expense is €0.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.00 is trading 8.5% below its estimated GF Value™ of €19.67.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Other Operating Expense: €0.41 Mil
GF Value™: €19.67 vs. price of €18.00 (8.5% below fair value)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
43GF Score
Get the complete analysis for OTSE:MOLNR
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
